Keros Therapeutics, Inc. 8-K

What Happened
Keros Therapeutics, Inc. announced that its Board voted on June 23, 2026 to appoint Anne Prener, M.D., Ph.D., as a director, effective July 1, 2026. Dr. Prener was named a Class III director with a term expiring at the Company’s 2029 annual meeting of stockholders and has not yet been assigned to any Board committees. The company issued a press release on June 25, 2026 disclosing the appointment (Exhibit 99.1 to the 8‑K). The Company will enter into its standard indemnification agreement with Dr. Prener.

Key Details

• Appointment effective: July 1, 2026; term through the 2029 annual meeting.
• Initial equity awards: option grant and restricted stock unit (RSU) award each with grant-date fair value of $150,000 (each capped at 0.075% of outstanding shares).
• Ongoing pay: annual option and RSU grants of $75,000 each (each capped at 0.0375% of outstanding shares) and a $41,500 annual cash retainer.
• Vesting: initial option and RSU vest quarterly over three years (full vest upon a Change in Control). No related-party transactions reported.

Why It Matters
Board appointments affect company governance and oversight. For investors, the filing signals a change in board composition and confirms the related director compensation (equity grants and cash retainer), which can create modest future dilution and compensation expense. The disclosure follows SEC rules and provides transparency about the appointment, timing, and material terms for Dr. Prener’s service.